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Abstract 
The first Rhinology Future Debates was held in Brussels in December 2016, organized by EUFOREA (European Forum for Research 
and Education in Allergy and Airways diseases). The purpose of these debates is to bring novel developments in the field of Rhino-
logy to the attention of the medical, paramedical and patient community, in a highly credible and balanced context. 
For the first time in Rhinology, a peer to peer scientific exchange with key experts in the field of rhinology and key medical col-
leagues from leading industries let to a brainstorming and discussion event on a number of hot issues in Rhinology.
Novel developments are presented by key experts from industry and/or key thought leaders in Rhinology, and then followed by 
a lively debate on the potential positioning of new developments in care pathways, the strengths and weaknesses of the novel 
development(s), and comparisons with existing and/or competing products, devices, and/or molecules.
As all debates are recorded and distributed on-line with limited editing (www.rhinology-future.com), EUFOREA aims at maxi-
mizing the education of the target groups on novel developments, allowing a critical appraisal of the future and a more rapid 
implementation of promising novel tools, techniques and/or molecules in clinical practise in Europe.
The next Rhinology Future debate will be held in Brussels in December 2017.
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Introduction
For the first time in Rhinology, EUFOREA brought together key 
experts in the field of rhinology and key medical persons from 
the leading industries for a brainstorming and discussion forum 
in Brussels. The topics that had been chosen for the debates 
reflect some of the current future trends in every day practise: 
biological treatment for CRSwNP, drug-eluting devices for CRS, 
navigation systems for sinus surgery, and balloon sinus dilata-
tion.
During 4 sessions of 1 hour, specific novel topics in Rhinology, 
that were fully recorded and distributed on-line via the Rhino-
logy future debates (www.rhinology-future.com, Figure 1) and 
EUFOREA (www.euforea.eu) websites. 
The purpose of this report is to summarize the major discussion 
points raised by the key opinion leaders that took part in the 
debates, and pave the way for a better and close collaboration 
between the medical community, the industry and even patient 
in the future.
The next Rhinology Future debate will be held in Brussels on 
Dec. 8, 2017.
New developments in biologicals for CRSwNP
In the first session, Professor Claire Hopkins highlighted the pre-
sent unmet needs in the treatment of patients with CRSwNP (1-4). 
She pointed out that the treatment heavily relies on corticoste-
roids, which when given systemically are eﬀective but only for a 
limited time period (5-7). Repeated use of systemic corticosteroids 
is restricted by potential serious side eﬀects like osteoporosis 
and the development of diabetes and hypertension. Surgery 
is eﬀective and the benefit remains relatively stable over time, 
however the revision rate is between 10% and 20% in 5 years 
(8-10) and up to 40% remain uncontrolled at 3 years after FESS 
(11). The treatments we have available at the moment, such as 
corticosteroids and antibiotics (12, 13) are relatively cheap and 
new treatment options need to be clinically eﬀective as well as 
cost-eﬀective. Monoclonal antibodies could be a potential new 
treatment when we can find the patients with the phenotype 
and endotype that will most benefit from these treatments. 
The ability to predict which patients will respond favourably to 
a certain monoclonal antibody will be a key issue in achieving 
costs-eﬀectiveness.
Two monoclonal antibodies were discussed in more detail: 
anti-IL4Ra blocker Dupilumab (Sanofi) that blocks the IL4/IL13 
receptor/ligand system (14) and AK001 (Allakos) that selectively 
blocks the Siglec-8, an inhibitory receptor that is present on 
mast cells and eosinophils (15). 
The discussion started oﬀ with the key question of positioning 
monoclonal antibodies in the treatment of CRSwNP in the 
future especially in comparison to surgery (16). The prevalence 
of CRSwNP is about 4-5% in the adult population (17). We do 
not know the exact prevalence of patients with severe disease 
needing repetitive surgery but Prof. Bachert estimated this to be 
around 1% of the population.
While surgery can be very eﬀective, there is a group of patients 
that needs multiple revision procedures. Such patients, who 
already have had repetitive surgery, are very interested to find 
alternatives. We would like to be able to discriminate the pa-
tients that will not react favourably to surgery but will respond 
to a certain monoclonal antibody to improve cost-eﬀectiveness. 
However, it was pointed out that improving the Quality of Life 
(QOL) of our patients, that are now often untreatable, is also very 
important. 
In chronic inflammatory respiratory disease, like CRSwNP and 
asthma, both the impact on QOL of the patients and the costs 
of the treatment will lead to data looking at costs per Quality 
adjusted Life Year (QALY). 
We still have an issue that the impact of the disease CRSwNP on 
QOL but also economically is not perceived as significant as, for 
example, in cardiovascular disease or diabetes. For that reason, 
it was emphasized that in clinical trials it is important to have 
standardised endpoints with emphasis on QOL, like SNOT-22 
and level of control of disease additional to polyp size (2). It is 
especially important to have measurements that can be used to 
compare to other diseases, like general QOL questionnaires and 
impact on work productivity (18-21). In registration trials, however, 
we are dependent on what the health authorities ask us, which 
is preferentially polyp size and symptoms. 
It was emphasized that evaluation of direct and indirect costs in 
large cohorts of patients in daily clinical care are needed to have 
a better understanding of the economic impact of the disease 
(18, 22). Especially, because most patients with CRSwNP are in the 
age group of the working population. Moreover, biologicals also 
impact the symptoms of lower airway disease in patients with 
Figure 1. Website of the rhinology future debates (www.rhinology-
future.com), where videos from the different panel discussion can be 
watched.
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point of view, this seems very feasible. In this way, we will be 
able to deliver precision medicine to our patients tailoring the 
most (cost) eﬀective treatment to our patients preferably early 
in the disease process (21, 29). Most of the surgeons in the panel 
believed that in the future the amount of surgery will be signi-
ficantly reduced and hopefully seldom be necessary, although 
they were not sure whether in some patients a singular surgery 
can be suﬃcient to prevent further development of the disease. 
However, this is very much dependent on the type of surgery; 
surgery approaches need to be tailored to the endotype/seve-
rity of inflammation in the future.
The panel concluded that there is a huge potential for mono-
clonal antibodies in the treatment of patients with CRSwNP but 
that there is a need to collaborate together to show the burden 
of disease and the burden of treatments that we oﬀer to our pa-
tients so to establish real personalised medicine to our patients 
(Figure 2).
Balloons in sinus surgery in Europe 
In the second session, we discussed the role of balloons in the 
treatment of CRS in Europe. Two examples of the potential role 
of balloons in the treatment of CRS were given. 
Entellus medical technologies presented their vision to move 
surgical treatment of CRS from the operating theatre to the 
ambulatory setting by providing instruments like balloons and 
instruments for suction and irrigation (30, 31). Medtronic provided 
the evidence available for the use of balloon sinus dilation. It 
was shown that flexible balloons often miss the natural ostium 
(32). For that reason, Medtronic developed a more rigid and 
image-guided balloon system. 
Finally, an example was shown of the SinuSys Vent-os system, a 
slow low-pressure balloon which further emphasizes the pos-
sibilities of ambulatory treatment.
Balloons can be combined with image-guidance to improve 
accuracy. However, there is still a debate going on about the 
precise indications and limitations of the technique.
The panel agreed that the balloon is an instrument that still 
needs to find its exact place in the treatment of CRS. 
The panel felt that potentially good candidates for balloon 
procedures could be patients with sinus obstruction and not 
primarily mucosal disease, special cases of acute rhinosinusitis, 
re-closure after surgery, approach in the oﬃce, relatively short 
procedures (less than one hour) in the oﬃce, giving the options 
of applying medication in sinus via balloon. The panel members 
were all confident that the patients suitable for balloon are not 
the same population as the patients suitable for FESS. Also, pa-
nellists expressed their worries about the potential stretching of 
indication for an intervention. At the moment, the panellists do 
not see indications for balloons in patients with severe CRS with 
mucosal disease like patients with CRSwNP.
co-morbidity and may have additional value in these patients.
A collaboration of the health professionals, the industry and the 
government could be ideal to follow a large cohort of patients 
to understand the impact of the disease not only on work pro-
ductivity but also the impact that the (treatment of ) the disease 
can have in the longer run. It could also lead to the develop-
ment of instruments that are internationally accepted by all 
parties to optimally measure impact of the disease. 
The panel was asked whether at the moment we have suﬃcient 
evidence for safety and eﬃcacy for monoclonal antibodies. At 
this moment, we do not have registration/licencing for mo-
noclonal antibodies for CRSwNP. However, there seems to be 
reasonable amount of data to show that monoclonal antibodies 
are safe, especially in the asthma literature in the literature 
concerning asthma, chronic urticaria and atopic dermatitis (23, 24). 
We need more studies in larger groups of patients to demon-
strate that monoclonal antibodies are safe over longer periods 
of time(25). 
Although we are able to endotype patients at the moment, we 
still need to combine that knowledge with the development 
of biomarkers to predict which patients will react favourably to 
monoclonal antibodies (26). Ideally, we should be able to discrimi-
nate these patients early in the disease and treat them early to 
prevent multiple surgeries in the years to follow and potentially 
also to prevent the development of lower airway disease (27, 28). 
Although, contrary to surgery, we currently do not have enough 
data at the moment to show that monoclonal antibodies can 
prevent the development of asthma from a pathophysiological 
Figure 2. Summary of the panel discussion on “New developments in 
biologicals for CRSwNP”.
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A problem in Europe is the reimbursement of the balloon. Alt-
hough in general the panellists feel it is potentially not an issue 
to add costs to the procedure, just like we use shaver blades, at 
the moment most balloons are very expensive compared to the 
total reimbursement. Although, it was noted during the discus-
sion that NICE, the National Institute for Clinical Excellence, was 
considering the utilization of the Entellus balloon technology in 
the UK’s NHS. 
The panellists are not convinced that the potential advances of 
low-pressure balloon technology, achieves suﬃcient trade-oﬀ 
with the relatively longer time the procedure takes.  
The trials available at the moment suﬀer from lack of control 
groups, lack of randomisation, short-term follow-up and type 
II-error (not diﬀerent is not the same as equal).  The panel-
lists would like to see randomised trials with balloons in large 
patients groups, preferably sham-controlled but otherwise in 
comparison with a FESS and a medical treatment arm and with 
long-term follow-up. The trials should be in a variety of well-
defined patient groups to be sure that the results are widely 
applicable. 
Relatively flexible balloons seem to be inherently safe procedu-
res; however, the more rigid balloons, and introducers, seem to 
have higher risks. The potential risks of penetration of the skull 
base and orbit are not unthinkable, cases have been reported 
(33, 34). Of course, complications are always made by the surgeon 
and not by the instrument.
We conclude that data to guide us in patient selection are extre-
mely important. We need good large randomized trials to give 
us a better understanding of the possibilities and the limitations 
of balloons. Cost-eﬀectiveness should be part of those studies 
(Figure 3).
Local treatment in CRS: Higher dose, longer availa-
bility
In the third session, we addressed the need for higher dose 
of local treatment in the sinuses. Two examples of high dose cor-
ticosteroid implants were presented. First the PROPEL® device 
from Intersect ENT was presented (35, 36). Bioinspire presented 
sinuband, a new bioabsorbable film that slowly delivers cortico-
steroids postoperatively (37).
It is indicated by the panel that these are promising new deve-
lopments to reduce systemic corticosteroids use while poten-
tially getting a higher dose in the sinuses. We also see great 
opportunities in treating frontal sinus disease diﬃcult to reach 
with local treatment and as an alternative to local treatment es-
pecially in cases where compliance is an issue. PROPEL implants 
are both FDA and CE mark approved for use in both ethmoid 
and frontal sinuses and the evidence supporting the technology 
was presented. It was mentioned that the Sinuband could have 
potential to cover bare bone especially in (more aggressive) 
frontal sinus surgery to provide a layer for the epithelium to 
grow over.  However, it was commented that synechia formation 
in general does not seem to be a big issue in most of our pa-
tients (38). Moreover, as was shown in the past (39) it takes months 
for lateralisation of the middle turbinate after surgery and there 
are easy ways to prevent this lateralisation (40). 
The panel discussed the diﬀerences between device and drug 
and the diﬀerent regulations in Europe. We discuss that we are 
in need of data comparing these new local ways of treatment 
with the conventional ways of local treatment, like nasal dou-
ches with steroids or nasal sprays for longer periods of time and 
in diﬀerent pheno- and endotypes.
The panellists express their interest in products that can be used 
directly after surgery and deliver a high dose of steroids especi-
ally in the postoperative period, preferably for a longer period of 
1-3 months but also in products that can easily be administered 
in the outpatient oﬃce setting ideally by placing a device/drug 
in between the polyps to deliver high doses of drug locally. 
The studies until now do show that it is not a problem to rinse 
extensively after placing the devices. The drugs are so lipophilic 
that it is not very likely that they are washed out. Also, the devi-
ces stay nicely in place when patients used rinsing (35-37). 
Some panellists indicated that they felt corticosteroids could 
reduce epithelial regrowth and that it is important to keep the 
bone covered with mucosa as much as possible. They indicated 
that these devices would be able to leave more of the mucosa 
and rely on the anti-inflammatory eﬀects of the drug. Other pa-
nellists voiced they do not worry at all about epithelial regrowth 
and point to studies actually improving the quality and growth 
of the mucosa after local corticosteroid usage (41-43).
Animal experimental studies, performed with Sinuband on mu-
cosa or on stripped bone, showed that the device does not have 
a negative eﬀect on wound healing (unpublished data). 
It is debated how much steroids are actually reaching the 
Figure 3. Summary of the panel discussion on “Balloons in sinus surgery 
in Europe”.
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mucosa. When the devices are placed in the sinuses, higher 
doses can be found in the sinuses and lower doses in the nasal 
cavity. Systemic exposure does not seem to be an issue for these 
devices (35-37). 
We conclude that these devices are promising and that we are 
very happy to design together with key opinion leaders from 
the companies and (university) hospitals the protocols to further 
study their role in contemporary treatment of the diﬀerent phe-
notypes and endotypes of CRS (Figure 4).
The place of navigation in daily practice
Seventy-five percent of the practices in the US now have naviga-
tion in comparison to almost 4000 hospitals and clinics (25%) in 
Europe. 
Two Image-guided surgery (IGS) systems were presented. The 
system of Medtronic and the Fiagon system. Dr A. Strzembosz, 
presenting the electro-magnetic system of Medtronic, pointed 
out that for the best performance and the best patient results 
familiarity with the navigation system and proper and regular 
usage are mandatory. Being unfamiliar with the system can lead 
to more stress than real help in situations that navigation could 
be of assistance. Navigation can be of help in complex proce-
dures but also potentially to do more complete surgery.  The 
navigation systems can support the decisions of the surgeon 
but can never replace his/her anatomical knowledge.
Dr. D. Mucha, presenting the Fiagon system, explained that also 
for him having the system in the clinical routine is important. 
The instruments are navigated at the tip to improve accuracy 
and ease of use. 
Contrary to some other societies, the European Rhinologic Soci-
ety until now decided not to produce guidelines on when to use 
navigation. The society felt that the surgeon remains responsible 
at all times (it is the surgeon that is behind the wheel) and that 
pointing to situations where the navigation could be or should 
be used would not be helpful.
The panel felt navigation can play a role in education and it can 
improve the learning curve. However, nobody felt that compli-
cations can be prevented by using a navigation system and this 
has also been shown in the literature (44). Moreover, some panel-
lists felt that it can might be a disadvantage and even dangerous 
when (younger) surgeons are so used to navigation, especially in 
a training situation, that they do not primarily rely on their ana-
tomical knowledge. Younger surgeons should also be trained in 
using IGS in a proper way. 
It was pointed out that FESS is the most litigated procedure in 
rhinology, but unfortunately navigation per se does not reduce 
the complication rate (44, 45).
The panellists felt it prudent that if navigation is used, to use 
it often to encourage familiarity with the technology and its 
limitations. However, it was not felt that the advantage of 
using IGS at the moment warrants its use in every case. If IGS 
is to be used it should be employed from the outset, to receive 
reconfirmation from the beginning of the surgery, in order to 
be comfortable with its use at a moment that it is most needed. 
The panel felt the IGS is helpful but not meant to help with mil-
limetric decisions. It was pointed out numerous times that it is 
always the surgeon and his/her anatomical knowledge that is 
most important. 
The question whether more complete surgery could be done 
with navigation was undecided. Surgeons having a more con-
servative philosophy perform less extensive surgery and believe 
that incomplete surgery does not mean less eﬀective surgery. 
There are no data at the moment linking the extent of the sur-
gery to patient outcomes.
Some panellists felt that navigation gives a more 3D feeling 
helping to improve their orientation. 
When the panellists were asked what irritated them most when 
using IGS, they mostly mentioned technical issues; especially 
when it is unclear why the system does not work. Most panellists 
felt the systems were still too erratic.
Moreover, panellists expressed that they did not like the issues 
with data handling: patients coming from outside with the CT 
scan and then the navigation system needing another sinus 
CT to fulfil the criteria of the system. Most panellists thought 
the systems were expensive and although they understand the 
advantages of disposables, they were not happy with the costs 
of the disposables nor the limited use of re-usables.
Panellists expressed their frustration that systems very often 
seem to become less precise during the procedure, especially in 
more prolonged cases. 
When asked what the panellists would really like to have in na-
vigation the following items were mentioned: wireless systems, 
easy to use, easy registration, and also repetition of registration 
Figure 4. Summary of the panel discussion on “Local treatment in CRS: 
Higher dose, longer availability”.
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must be very easy.
Some panellists would like to have the possibility of seeing a 
3D view in the navigation and it was suggested that it would be 
very helpful to have superposition the coronal view of the CT 
superimposed on the endoscopic view.
Some panellists liked the ability of being able to make all instru-
ments navigated, also disposable instruments at minimal costs, 
but others only used navigated pointers and/or suction.
Costs are a big issue, so companies should work on aﬀordable 
systems and disposables.
The companies indicated that many of the irritations can and 
will be solved in the near future and that many of the dreams 
are worked on, like having wireless instruments. Some are a little 
bit more complicated like superimposing the coronal view on 
the endoscopic view.
The university KOLs again expressed that they think that guide-
lines, position papers and recommendations for the use of na-
vigation were not helpful and that for that reason the European 
bodies like EUFOREA or ERS are not planning to write these.
It is concluded that navigation is certainly an advantage, we 
would not like to live without it, but ideally it should be cheaper, 
more reliable and user friendly. In the meantime, it was felt to be 
important to convince the health payers that the price is worth 
it and the use of navigation should be reimbursed (Figure 5). 
Conclusion
For the first time in Rhinology, a peer to peer scientific exchange 
with key experts in the field of rhinology and key medical colle-
agues from leading industries let to a brainstorming and discus-
sion event on a number of hot issues in Rhinology. All panellists 
felt the discussions were extremely valuable and a follow-up will 
be organized in December 2017.
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